vatelizumab

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 470629425

| type = mab

| image =

| alt =

| mab_type = mab

| source = zu

| target = integrin alpha 2

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1238217-55-4

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = A4R7G50030

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Vatelizumab is an immunomodulator. It binds to integrin alpha 2.{{cite journal|author=World Health Organization|year=2011|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105|url=https://www.who.int/medicines/publications/druginformation/innlists/INNprepub105.pdf|journal=WHO Drug Information|volume=25|issue=2}}

It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.{{cite journal |vauthors=Mozaffari S, Nikfar S, Abdollahi M |title=Inflammatory bowel disease therapies discontinued between 2009 and 2014 |journal=Expert Opin Investig Drugs |volume=24 |issue=7 |pages=949–56 |date=2015 |pmid=25861835 |doi=10.1517/13543784.2015.1035432 |s2cid=26104155 }}